Circulatory lability and myocardial stress in cardiovascular surgical patients.

P. Sechzer,J. Wachtel,A. S. Keats

1969-09-01

Abstract:

What problem does this paper attempt to address?

Discovery of 4,6-Pyrimidinediamine Derivatives As Novel Dual EGFR/FGFR Inhibitors Aimed EGFR/FGFR1-positive NSCLC.

Zixin Xie,Kaiqi Wu,Yuexuan Wang,Yaqian Pan,Bo Chen,Donghua Cheng,Suwei Pan,Taoning Guo,Xuze Du,Longcheng Fang,Xuebao Wang,Faqing Ye

DOI: https://doi.org/10.1016/j.ejmech.2019.111943

IF: 7.088

2019-01-01

European Journal of Medicinal Chemistry

Abstract:FGF2-FGFR1 autocrine pathway activation reduces the sensitivity of non-small cell lung cancer (NSCLC) cells to EGFR inhibitors like Gefitinib. Therefore, dual-specific drugs targeting EGFR and FGFR with high selectivity and activity are required. Through structure analysis of excellent EGFR inhibitors and FGFR inhibitors, we designed and synthesized 33 4,6-pyrimidinediamine derivatives as dual EGFR and FGFR inhibitors and selected BZF 2 as a potential EGFR and FGFR inhibitor after initial cell screening. Then, through kinase testing and western blot analysis, BZF 2 was defined as a dual EGFR and FGFR inhibitor with high selectivity 1and activity. Biological evaluation of NSCLC cell lines with the FGF2-FGFR1 autocrine loop indicated that BZF 2 significantly inhibited cell proliferation (IC50 values for H226 and HCC827 GR were 2.11 μM, and 0.93 μM, respectively), cell migration, and induced cell apoptosis and cell cycle arrest. Anti-tumor activity test in vivo showed that BZF 2 obviously shrank tumor size. Therefore, BZF 2 is a highly selective and potent dual EGFR/FGFR compound with promising therapeutic effects against EGFR/FGFR1-positive NSCLC.
Design, synthesis, and biological evaluation of selective covalent inhibitors of FGFR4

Xiaojuan Chen,Huiliang Li,Qianmeng Lin,Shuyan Dai,Lingzhi Qu,Ming Guo,Lin Zhang,Jiaxuan Liao,Hudie Wei,Guangyu Xu,Longying Jiang,Yongheng Chen

DOI: https://doi.org/10.1016/j.ejmech.2024.116281

IF: 7.088

2024-02-01

European Journal of Medicinal Chemistry

Abstract:Aberrant signaling via fibroblast growth factor 19 (FGF19)/fibroblast growth factor receptor 4 (FGFR4) has been identified as a driver of tumorigenesis and the development of many solid tumors, making FGFR4 is a promising target for anticancer therapy. Herein, we designed and synthesized a series of bis-acrylamide covalent FGFR4 inhibitors and evaluated their inhibitory activity against FGFRs, FGFR4 mutants, and their antitumor activity. CXF-007, verified by mass spectrometry and crystal structures to form covalent bonds with Cys552 of FGFR4 and Cys488 of FGFR1, exhibited stronger selectivity and potent inhibitory activity for FGFR4 and FGFR4 cysteine mutants. Moreover, CXF-007 exhibited significant antitumor activity in hepatocellular carcinoma cell lines and breast cancer cell lines through sustained inhibition of the FGFR4 signaling pathway. In summary, our study highlights a novel covalent FGFR4 inhibitor, CXF-007, which has the potential to overcome drug-induced FGFR4 mutations and might provide a new strategy for future anticancer drug discovery.

chemistry, medicinal
Design, synthesis, and biological evaluation of 1,6-naphthyridine-2-one derivatives as novel FGFR4 inhibitors for the treatment of colorectal cancer

Bo Fang,Yinshuang Lai,Hao Yan,Yue Ma,Zefeng Ni,Qianqian Zhu,Jianxia Zhang,Yanfei Ye,Mengying Wang,Peipei Wang,Yan Wang,Shuyuan Zhang,Min Hui,Dalong Wang,Yunjie Zhao,Xiaokun Li,Kun Wang,Zhiguo Liu

DOI: https://doi.org/10.1016/j.ejmech.2023.115703

IF: 7.088

2023-08-09

European Journal of Medicinal Chemistry

Abstract:Aberrant FGFR4 signaling has been implicated in the development of several cancers, making FGFR4 a promising target for cancer therapy. Several FGFR4-selective inhibitors have been developed, yet none of them have been approved. Herein, we report a novel series of 1,6-naphthyridine-2-one derivatives as potent and selective inhibitors targeting FGFR4 kinase. Preliminary structure-activity relationship analysis was conducted. The screening cascades revealed that 19g was the preferred compound among the prepared series. 19g demonstrated excellent kinase selectivity and substantial cytotoxic effect against all tested colorectal cancer cell lines. 19g induced significant tumor inhibition in a HCT116 xenograft mouse model without any apparent toxicity. Notably, 19g exhibited excellent potency in disrupting the phosphorylation of FGFR4 and downstream signaling proteins mediated by FGF18 and FGF19. Compound 19g might be a potential antitumor drug candidate for the treatment of colorectal cancer.

chemistry, medicinal
Discovery of potent CSK inhibitors through integrated virtual screening and molecular dynamic simulation

Roufen Chen,Yuchen Wang,Zheyuan Shen,Chenyi Ye,Yu Guo,Yan Lu,Jianjun Ding,Xiaowu Dong,Donghang Xu,Xiaoli Zheng

DOI: https://doi.org/10.1002/ardp.202400066

2024-05-30

Archiv der Pharmazie

Abstract:A hybrid virtual screening workflow, integrating methods such as Attentive FP, molecular docking, and molecular mechanics generalized Born surface area (MM/GBSA), was employed to identify a highly potent C‐terminal Src kinase (CSK) inhibitor, molecule 2. This compound demonstrated substantial growth suppression in various triple‐negative breast cancer cell lines and resulted in pronounced G1 phase accumulation and enhanced cell apoptosis. Oncogenic overexpression or activation of C‐terminal Src kinase (CSK) has been shown to play an important role in triple‐negative breast cancer (TNBC) progression, including tumor initiation, growth, metastasis, drug resistance. This revelation has pivoted the focus toward CSK as a potential target for novel treatments. However, until now, there are few inhibitors designed to target the CSK protein. Responding to this, our research has implemented a comprehensive virtual screening protocol. By integrating energy‐based screening methods with AI‐driven scoring functions, such as Attentive FP, and employing rigorous rescoring methods like Glide docking and molecular mechanics generalized Born surface area (MM/GBSA), we have systematically sought out inhibitors of CSK. This approach led to the discovery of a compound with a potent CSK inhibitory activity, reflected by an IC50 value of 1.6 nM under a homogeneous time‐resolved fluorescence (HTRF) bioassay. Subsequently, molecule 2 exhibits strong growth inhibition of MD anderson ‐ metastatic breast (MDA‐MB) ‐231, Hs578T, and SUM159 cells, showing a level of growth inhibition comparable to that observed with dasatinib. Treatment with molecule 2 also induced significant G1 phase accumulation and cell apoptosis. Furthermore, we have explored the explicit binding interactions of the compound with CSK using molecular dynamics simulations, providing valuable insights into its mechanism of action.

pharmacology & pharmacy,chemistry, medicinal, multidisciplinary
Virtual screening, molecular dynamics simulations, and in vitro validation of EGFR inhibitors as breast cancer therapeutics

Swathi R Shetty,Sudhan Debnath,Khokan Majumdar,Muthukumaran Rajagopalan,Amutha Ramaswamy,Amitava Das

DOI: https://doi.org/10.1016/j.bioorg.2024.107849

2024-10-01

Abstract:A high abundance of Epidermal Growth Factor Receptor (EGFR) in malignant cells makes them a prospective therapeutic target for basal breast tumors. Although EGFR inhibitors are in development as anticancer therapeutics, there exists limitations due to the dose-limiting cytotoxicity that limits their clinical utilization, thereby necessitating the advancement of effective inhibitors. In the present study, we have developed common pharmacophore hypotheses using 30 known EGFR inhibitors. The best pharmacophore hypothesis DHRRR_1 was utilized for virtual screening (VS) of the Phase database containing 4.3 × 106 fully prepared compounds. The top 1000 hits were further subjected to ADME filtration followed by structure-based VS and Molecular Dynamics (MD) simulation investigations. Based on pharmacophore hypothesis matching, XP glide score, interactions between ligands and active site residues, ADME properties, and MD simulations, the five best hits (SN-01 through SN-05) were preferred for in-vitro cytotoxicity studies. All the molecules except SN-02 exhibited cytotoxicity in Triple Negative Breast Cancer (TNBC) cells. These potential EGFR inhibitors effectively downregulated the EGF-induced proliferation, migration, in-vitro tumorigenic capability, and EGFR activation (pEGFR) in the TNBCs. Additionally, in combination with doxorubicin, the identified EGFR inhibitors significantly decreased the EGF-induced proliferation. SN-04, and SN-05 in the presence of a lower concentration of doxorubicin markedly increased the apoptotic markers expression in the TNBCs, an effect which was comparable to a higher concentration of doxorubicin treatment, alone. These observations suggest that both SN-04 and/or SN-05 can improve the efficacy of chemotherapeutic drug, doxorubicin at a lower concentration to avert the higher dose of chemotherapeutic-induced side effects during breast cancer treatment.
Discovery of the First-in-Class Dual-Target ROCK/HDAC Inhibitor with Potent Antitumor Efficacy in Vivo That Trigger Antitumor Immunity

Churu Mao,Jiebin Fang,Shijie Zou,Yun Huang,Xiaoming Chen,Xia Ding,Zhangyun Fang,Ningjing Zhang,Yijie Lou,Zhe Chen,Wanjing Ding,Zhongjun Ma

DOI: https://doi.org/10.1021/acs.jmedchem.4c02183

IF: 8.039

2024-01-01

Journal of Medicinal Chemistry

Abstract:Triple-negative breast cancer (TNBC) represents a highly aggressive and heterogeneous malignancy. Currently, multitarget drug approaches present a promising therapeutic approach for TNBC. Utilizing a combinatorial chemistry strategy to construct a virtual screening database, dual ROCK/HDAC-targeting benzothiophene compounds were identified. Notably, compound 10h effectively inhibits ROCK1/2 and HDAC1/2/3/6/8 while demonstrating potent antiproliferative activity against breast cancer cells. In an orthotopic mouse model of breast cancer, 10h significantly suppressed tumor growth without apparent toxicity. Importantly, 10h induced immunogenic cell death (ICD), promoted dendritic cells (DCs) maturation, and activated T cells, thereby initiating antitumor immunity. In conclusion, compound 10h is a novel dual-target ROCK/HDAC inhibitor that represents a promising treatment strategy for TNBC.
Discovery of Novel Epidermal Growth Factor Receptor (EGFR) Inhibitors Using Computational Approaches

Donghui Huo,Shiyu Wang,Yue Kong,Zijian Qin,Aixia Yan

DOI: https://doi.org/10.1021/acs.jcim.1c00884

IF: 6.162

2021-12-21

Journal of Chemical Information and Modeling

Abstract:The epidermal growth factor receptor (EGFR) signaling pathway plays an important role in cell growth, proliferation, differentiation, and other physiological processes, which makes the EGFR a promising target for anticancer therapies. The discovery of novel EGFR inhibitors may provide a solution to the problem of drug resistance. In this work, we performed a ligand-based virtual screening (LBVS) protocol for finding novel EGFR inhibitors from a 5.3 million compound library. First, the 3D shape-based similarity was used to obtain structurally novel EGFR inhibitors. In this study, we tried three queries; two were crystal structures and one was generated from deep generative models of graphs (DGMG). Next, we have built four structure-activity relationship (SAR) models and three quantitative structure-activity relationship (QSAR) models based on an SVM method for further screening of highly active EGFR inhibitors. Experimental validations led to the identification of nine hits out of 18 tested compounds. Among them, hit 1, hit 5, and hit 6 had IC50 values around 80 nM against EGFR whose interactions with EGFR were further investigated by molecular dynamics simulations.

chemistry, multidisciplinary, medicinal,computer science, interdisciplinary applications, information systems
High-Throughput Empirical and Virtual Screening to Discover Novel Inhibitors of Polyploid Giant Cancer Cells in Breast Cancer

Yushu Ma,Chien-Hung Shih,Jinxiong Cheng,Hsiao-Chun Chen,Li-Ju Wang,Yanhao Tan,Yu-Chiao Chiu,Yu-Chih Chen

DOI: https://doi.org/10.1101/2024.09.23.614522

2024-09-24

Abstract:Therapy resistance in breast cancer is increasingly attributed to polyploid giant cancer cells (PGCCs), which arise through whole-genome doubling and exhibit heightened resilience to standard treatments. Characterized by enlarged nuclei and increased DNA content, these cells tend to be dormant under therapeutic stress, driving disease relapse. Despite their critical role in resistance, strategies to effectively target PGCCs are limited, largely due to the lack of high-throughput methods for assessing their viability. Traditional assays lack the sensitivity needed to detect PGCC-specific elimination, prompting the development of novel approaches. To address this challenge, we developed a high-throughput single-cell morphological analysis workflow designed to differentiate compounds that selectively inhibit non-PGCCs, PGCCs, or both. Using this method, we screened a library of 2,726 FDA Phase 1-approved drugs, identifying promising anti-PGCC candidates, including proteasome inhibitors, FOXM1, CHK, and macrocyclic lactones. Notably, RNA-Seq analysis of cells treated with the macrocyclic lactone Pyronaridine revealed AXL inhibition as a potential strategy for targeting PGCCs. Although our single-cell morphological analysis pipeline is powerful, empirically testing all existing compounds is impractical and inefficient. To overcome this limitation, we trained a machine learning model to predict anti-PGCC efficacy in silico, integrating chemical fingerprints and compound descriptions from prior publications and databases. The model demonstrated a high correlation with experimental outcomes and predicted efficacious compounds in an expanded library of over 6,000 drugs. Among the top-ranked predictions, we experimentally validated two compounds as potent PGCC inhibitors. These findings underscore the synergistic potential of integrating high-throughput empirical screening with machine learning-based virtual screening to accelerate the discovery of novel therapies, particularly for targeting therapy-resistant PGCCs in breast cancer.

Bioengineering
Active and machine learning-enhanced discovery of new FGFR3 inhibitor, Rhapontin, through virtual screening of receptor structures and anti-cancer activity assessment

Qingxin Zeng,Haichuan Hu,Zhengwei Huang,Aotian Guo,Sheng Lu,Wenbin Tong,Zhongheng Zhang,Tao Shen

DOI: https://doi.org/10.3389/fmolb.2024.1413214

IF: 6.113

2024-06-12

Frontiers in Molecular Biosciences

Abstract:Introduction: This study bridges traditional remedies and modern pharmacology by exploring the synergy between natural compounds and Ceritinib in treating Non-Small Cell Lung Cancer (NSCLC), aiming to enhance efficacy and reduce toxicities. Methods: Using a combined approach of computational analysis, machine learning, and experimental procedures, we identified and analyzed PD173074, Isoquercitrin, and Rhapontin as potential inhibitors of fibroblast growth factor receptor 3 (FGFR3). Machine learning algorithms guided the initial selection, followed by Quantitative Structure-Activity Relationship (QSAR) modeling and molecular dynamics simulations to evaluate the interaction dynamics and stability of Rhapontin. Physicochemical assessments further verified its drug-like properties and specificity. Results: Our experiments demonstrate that Rhapontin, when combined with Ceritinib, significantly suppresses tumor activity in NSCLC while sparing healthy cells. The molecular simulations and physicochemical evaluations confirm Rhapontin's stability and favorable interaction with FGFR3, highlighting its potential as an effective adjunct in NSCLC therapy. Discussion: The integration of natural compounds with established cancer therapies offers a promising avenue for enhancing treatment outcomes in NSCLC. By combining the ancient wisdom of natural remedies with the precision of modern science, this study contributes to evolving cancer treatment paradigms, potentially mitigating the side effects associated with current therapies.

biochemistry & molecular biology
PO-462 Investigating the Potential Anti-Cancer Properties of a Novel Src Family Kinase Inhibitor in Triple Negative Breast Cancer

H.C. Leong,M.M. Kanchi,S.M. Kumaraswarmy,T.Z. Tan,V. Pandey,R.Y.J. Huang,P.E. Lobie,B. Salundi,G. Sethi,A.P. Kumar

DOI: https://doi.org/10.1136/esmoopen-2018-eacr25.483

IF: 6.883

2018-01-01

ESMO Open

Abstract:Introduction The Src Family Kinases (SFKs) are key mediators in various oncogenic pathways and are commonly activated in many forms of cancer. Of the nine members of SFKs, increasing reports suggest aberrant activation of Lyn and Fyn in breast cancer. Bioinformatics analysis reveals that Lyn and Fyn expression are strongly associated with the claudin-low TNBC patient group. Due to the current lack of targeted therapy for the TNBC subtype, it becomes worthwhile to investigate the potential of Lyn and Fyn as novel therapeutic targets. While preclinical studies involving current SFK inhibitors were promising, subsequent clinical trials have shown limited clinical benefits. In this project, we developed a novel in-house SFK inhibitor (Drug X) that specifically targets Lyn and Fyn kinases. Material and methods Patient data analysis, Ligand-based computation, Proteome Profiler Array, in vivo mouse Pharmacokinetics and Pharmacodynamics studies, Bioinformatics analysis, Affymetrix Microarray, Secretome Analysis, Cell viability assays, Flow cytometry, Western blot, qPCR, Immunofluorescence, Transwell assays, 3D Matrigel Assays, and Tube-formation assay. Results and discussions Proteome Profiler Array results validated the ligand-based target prediction analyses of Drug X in vitro. Mouse studies show that Drug X is well-tolerated and exhibited significant tumour burden load reduction. Pharmacokinetics of Drug X was characterised. Overall, Drug X showed moderate systemic clearance, high volume of distribution and moderate oral bioavailability. Downstream functional studies were performed, and Drug X was found to induce apoptosis via the intrinsic pathway. Also, Drug X could down-regulate the mesenchymal properties of mesenchymal-like TNBC cell lines via the modulation of key EMT-related genes. Preliminary in vitro and in vivo rat aortic ring assay data also suggested that Drug X could harbour potent anti-angiogenic effects. Conclusion Based on in vitro and in vivo experiments, preliminary findings have supported that Drug X could potentially be a promising novel drug candidate for TNBC treatment and on-going efforts are being made to further elucidate the underlying mechanisms of Drug X in modulating the key oncogenic processes – namely from the angle of apoptosis, EMT and angiogenesis.
Discovery of Dual FGFR4 and EGFR Inhibitors by Machine Learning and Biological Evaluation

Xingye Chen,Wuchen Xie,Yan Yang,Yi Hua,GuoMeng Xing,Li Liang,Chenglong Deng,Yuchen Wang,Yuanrong Fan,Haichun Liu,Tao Lu,Yadong Chen,Yanmin Zhang

DOI: https://doi.org/10.1021/acs.jcim.0c00652

IF: 6.162

2020-09-14

Journal of Chemical Information and Modeling

Abstract:Kinase inhibitors are widely used in antitumor research, but there are still many problems such as drug resistance and off-target toxicity. A more suitable solution is to design a multitarget inhibitor with certain selectivity. Herein, computational and experimental studies were applied to the discovery of dual inhibitors against FGFR4 and EGFR. A quantitative structure–property relationship (QSPR) study was carried out to predict the FGFR4 and EGFR activity of a data set consisting of 843 and 5088 compounds, respectively. Four different machine learning methods including support vector machine (SVM), random forest (RF), gradient boost regression tree (GBRT), and XGBoost (XGB) were built using the most suitable features selected by the mutual information algorithm. As for FGFR4 and EGFR, SVM showed the best performance with R2test-FGFR4 = 0.80 and R2test-EGFR = 0.75, demonstrating excellent model stability, which was used to predict the activity of some compounds from an in-house database. Finally, compound 1 was selected, which exhibits inhibitory activity against FGFR4 (IC50 = 86.2 nM) and EGFR (IC50 = 83.9 nM) kinase, respectively. Furthermore, molecular docking and molecular dynamics simulations were performed to identify key amino acids for the interaction of compound 1 with FGFR4 and EGFR. In this paper, the machine-learning-based QSAR models were established and effectively applied to the discovery of dual-target inhibitors against FGFR4 and EGFR, demonstrating the great potential of machine learning strategies in dual inhibitor discovery.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jcim.0c00652?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jcim.0c00652</a>.Supporting Methods: Y-randomization test (p 2). Supporting Figures: Figure S1. The relationship between Q2 and the number of descriptors for FGFR4. Figure S2. Distribution of Q2 of randomized models compared with the true model in the Y-randomization test. Figure S3. Correlograms between each important descriptor and permeability values of two activity prediction modeling: (a) FGFR4, (b) EGFR. Figure S4. Comparison of the molecular similarity between the training set and the external set: (a) FGFR4 data set, (b) EGFR data set. Figure S5. Structures of compounds 1–3. Figures S6 and S7. The chemical structures of modeling molecules of the FGFR4/EGFR activity prediction model. Figure S8. The chemical structures of 23 compounds external verification set. Figure S9. Docking results of FGFR4 and EGFR. (<a class="ext-link" href="/doi/suppl/10.1021/acs.jcim.0c00652/suppl_file/ci0c00652_si_001.pdf">PDF</a>)Table S1. Experimental and predicted IC50 values of FGFR4 of the whole data set that consisted of 843 compounds. Table S2. Experimental and predicted IC50 values of EGFR of the whole data set that consisted of 5088 compounds. Table S3. Detailed information for the external validation set. Table S4. Statistical analysis of 180 descriptors selected in FGFR4 activity prediction. Table S5. Statistical analysis of 280 descriptors selected in EGFR activity prediction. Table S6. Detailed information on the most essential variables for FGFR4 prediction activity modeling. Table S7. Detailed information on the most essential variables for EGFR prediction activity modeling. Table S8. The original data for cross-docking of FGFR4 and EGFR. Table S9. Residue-specific binding free energies of FGFR4 (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4UXQ">4UXQ</a>) and compound 1. Table S10. Residue-specific binding free energies of EGFR (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ZAU">4ZAU</a>) and compound 1. (<a class="ext-link" href="/doi/suppl/10.1021/acs.jcim.0c00652/suppl_file/ci0c00652_si_002.xlsx">XLSX</a>)This article has not yet been cited by other publications.

chemistry, multidisciplinary, medicinal,computer science, interdisciplinary applications, information systems
Design and synthesis of dual BRD4/Src inhibitors for treatment of triple-negative breast cancer

Ying Wang,Aima Huang,Lu Chen,Fan Sun,Man Zhao,Ming Zhang,Yubao Xie,Shiyu Xu,Min Li,Liang Hong,Guofeng Li,Rui Wang

DOI: https://doi.org/10.1016/j.ejmech.2023.116009

IF: 7.088

2023-12-01

European Journal of Medicinal Chemistry

Abstract:Triple-negative breast cancer (TNBC) is an extremely aggressive tumor with limited treatment options and effectiveness. Dual-target inhibitors capable of simultaneously suppressing invasion may represent a promising therapeutic approach for TNBC. In this work, we developed a series of dual BRD4/Src inhibitors by connecting JQ1 and dasatinib using various linkers and evaluated their efficacy against TNBC both in vitro and in vivo . Among these compounds, HL403 demonstrated IC 50 values of 133 nM for BRD4 inhibition and 4.5 nM for Src inhibition. Most importantly, HL403 not only exhibited potent anti-proliferative capabilities, but also effectively suppressed the invasion of MDA-MB-231 cells in vitro . Finally, the anti-tumor efficacy of HL403 was validated in a mouse MDA-MB-231 xenograft tumor model, achieving a tumor growth inhibition (TGI) of 70.7 %, which was superior to the combination of JQ1 and dasatinib (TGI = 54.0 %). Our research provides a promising and feasible new strategy for significantly improving the treatment of TNBC.

chemistry, medicinal
Identification of New EGFR Inhibitors by Structure-Based Virtual Screening and Biological Evaluation

Shuyi Wang,Xiaotian Xu,Chuxin Pan,Qian Guo,Qinlan Li,Shanhe Wan,Zhonghuang Li,Jiajie Zhang,Xiaoyun Wu

DOI: https://doi.org/10.3390/ijms25031887

IF: 5.6

2024-02-05

International Journal of Molecular Sciences

Abstract:Epidermal growth factor receptor (EGFR) inhibitors have been used in clinical for the treatment of non-small-cell lung cancer for years. However, the emergence of drug resistance continues to be a major problem. To identify potential inhibitors, molecular docking-based virtual screening was conducted on ChemDiv and Enamine commercial databases using the Glide program. After multi-step VS and visual inspection, a total of 23 compounds with novel and varied structures were selected, and the predicted ADMET properties were within the satisfactory range. Further molecular dynamics simulations revealed that the reprehensive compound ZINC49691377 formed a stable complex with the allosteric pocket of EGFR and exhibited conserved hydrogen bond interactions with Lys 745 and Asp855 of EGFR over the course of simulation. All compounds were further tested in experiments. Among them, the most promising hit ZINC49691377 demonstrated excellent anti-proliferation activity against H1975 and PC-9 cells, while showing no significant anti-proliferation activity against A549 cells. Meanwhile, apoptosis analysis indicated that the compound ZINC49691377 can effectively induce apoptosis of H1975 and PC-9 cells in a dose-dependent manner, while having no significant effect on the apoptosis of A549 cells. The results indicate that ZINC49691377 exhibits good selectivity. Based on virtual screening and bioassays, ZINC4961377 can be considered as an excellent starting point for the development of new EGFR inhibitors.

biochemistry & molecular biology,chemistry, multidisciplinary
Unveiling the therapeutic potential: KBU2046 halts triple-negative breast cancer cell migration by constricting TGF-β1 activation in vitro

Jinxia Chen,Suli Dai,Geng Zhang,Sisi Wei,Xuetao Zhao,Yang Zheng,Yaojie Wang,Xiaohan Wang,Yunjiang Liu,Lianmei Zhao

DOI: https://doi.org/10.32604/or.2024.049348

2024-10-16

Abstract:Background: Triple-negative breast cancer (TNBC) is a heterogeneous, recurring cancer characterized by a high rate of metastasis, poor prognosis, and lack of efficient therapies. KBU2046, a small molecule inhibitor, can inhibit cell motility in malignant tumors, including breast cancer. However, the specific targets and the corresponding mechanism of its function remain unclear. Methods: In this study, we employed (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H tetrazolium) (MTS) assay and transwell assay to investigate the impact of KBU2046 on the proliferation and migration of TNBC cells in vitro. RNA-Seq was used to explore the targets of KBU2046 that inhibit the motility of TNBC. Finally, confirmed the predicted important signaling pathways through RT-qPCR and western blotting. Results: In this study, we found that KBU2046 functioned as a novel transforming growth factor-β (TGF-β1) inhibitor, effectively suppressing tumor cell motility in vitro. Mechanistically, it directly down-regulated leucine-rich repeat-containing 8 family, member E (LRRC8E), latent TGFβ-binding protein 3 (LTBP3), dynein light chain 1 (DNAL1), and MAF family of bZIP transcription factors (MAFF) genes, along with reduced protein expression of the integrin family. Additionally, KBU2046 decreased phosphorylation levels of Raf and ERK. This deactivation of the ERK signaling pathway impeded cancer invasion and metastasis. Conclusions: In summary, these findings advocate for the utilization of TGF-β1 as a diagnostic and prognostic biomarker and as a therapeutic target in TNBC. Furthermore, our data underscore the potential of KBU2046 as a novel therapeutic strategy for combating cancer metastasis.
Discovery of a small molecule ligand of FRS2 that inhibits invasion and tumor growth

Karthiga Santhana Kumar,Cyrill Brunner,Matthias Schuster,Levi Luca Kopp,Alexandre Gries,Shen Yan,Simon Jurt,Kerstin Moehle,Dominique Bruns,Michael Grotzer,Oliver Zerbe,Gisbert Schneider,Martin Baumgartner

DOI: https://doi.org/10.1007/s13402-022-00753-x

Abstract:Purpose: Aberrant activation of the fibroblast growth factor receptor (FGFR) family of receptor tyrosine kinases drives oncogenic signaling through its proximal adaptor protein FRS2. Precise disruption of this disease-causing signal transmission in metastatic cancers could stall tumor growth and progression. The purpose of this study was to identify a small molecule ligand of FRS2 to interrupt oncogenic signal transmission from activated FGFRs. Methods: We used pharmacophore-based computational screening to identify potential small molecule ligands of the PTB domain of FRS2, which couples FRS2 to FGFRs. We confirmed PTB domain binding of molecules identified with biophysical binding assays and validated compound activity in cell-based functional assays in vitro and in an ovarian cancer model in vivo. We used thermal proteome profiling to identify potential off-targets of the lead compound. Results: We describe a small molecule ligand of the PTB domain of FRS2 that prevents FRS2 activation and interrupts FGFR signaling. This PTB-domain ligand displays on-target activity in cells and stalls FGFR-dependent matrix invasion in various cancer models. The small molecule ligand is detectable in the serum of mice at the effective concentration for prolonged time and reduces growth of the ovarian cancer model in vivo. Using thermal proteome profiling, we furthermore identified potential off-targets of the lead compound that will guide further compound refinement and drug development. Conclusions: Our results illustrate a phenotype-guided drug discovery strategy that identified a novel mechanism to repress FGFR-driven invasiveness and growth in human cancers. The here identified bioactive leads targeting FGF signaling and cell dissemination provide a novel structural basis for further development as a tumor agnostic strategy to repress FGFR- and FRS2-driven tumors.
Design, Synthesis, and Biological Evaluation of Aminoindazole Derivatives as Highly Selective Covalent Inhibitors of Wild-Type and Gatekeeper Mutant FGFR4

Min Shao,Xiaojuan Chen,Fang Yang,Xiaojuan Song,Yang Zhou,Qianmeng Lin,Ying Fu,Raquel Ortega,Xiaojing Lin,Zhengchao Tu,Adam V. Patterson,Jeff B. Smaill,Yongheng Chen,Xiaoyun Lu

DOI: https://doi.org/10.1021/acs.jmedchem.2c00096

IF: 8.039

2022-03-10

Journal of Medicinal Chemistry

Abstract:Aberrant FGF19/FGFR4 signaling has been shown to be an oncogenic driver of growth and survival in human hepatocellular carcinoma (HCC) with several pan-FGFR inhibitors and FGFR4-selective inhibitors currently being evaluated in the clinic. However, FGFR4 gatekeeper mutation induced acquired resistance remains an unmet clinical challenge for HCC treatment. Thus, a series of aminoindazole derivatives were designed and synthesized as new irreversible inhibitors of wild-type and gatekeeper mutant FGFR4. One representative compound (7v) exhibited excellent potency against FGFR4, FGFR4V550L, and FGFR4V550M with nanomolar activity in both the biochemical and cellular assays while sparing FGFR1/2/3. While compound 7v demonstrated modest in vivo antitumor efficacy in nude mice bearing the Huh-7 xenograft model consistent with its unfavorable pharmacokinetic properties, it provides a promising new starting point for future drug discovery combating FGFR4 gatekeeper mediated resistance in HCC patients.The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acs.jmedchem.2c00096.The synthesis of target compound 6 and intermediates 17 and 27, selectivity study of 7v; pharmacokinetic parameters of 7v in SD rats; X-ray data collection of 7v and NMR spectra; and HRMS and HPLC analytics of representative compounds 6, 7, 7a-7za, and 8 (PDF)Molecular formula strings and IC50 values of compounds against FGFR1–3 wild-type kinases, FGFR4WT/V550L/V550M/C552S kinases, BaF3 FGFR4WT/V550L/V550M/C552S, MDA-MB-453, Hep3B, Huh-7, and JHH-7 cancer cells (CSV)Co-crystal structure of compound 7v with FGFR4V550M (PDB: 7WCX) (PDF)Co-crystal structure of compound 7v with FGFR4V550L (PDB: 7WCW) (PDF)Co-crystal structure of compound 7v with FGFR4WT (PDB: 7WCT) (PDF)This article has not yet been cited by other publications.

chemistry, medicinal
Discovery of novel dual VEGFR2 and Src inhibitors using a multistep virtual screening approach

Chen Shangying,Qin Chu,Sin Jia En,Yang Xuan,Tao Lin,Zeng Xian,Zhang Peng,Gao Chun Mei,Jiang Yu Yang,Zhang Cheng,Chen Yu Zong,Chui Wai Keung

DOI: https://doi.org/10.4155/fmc-2016-0162

2017-01-01

Future Medicinal Chemistry

Abstract:Aim: Simultaneous inhibition of VEGFR2 and Src may enhance the efficacy of VEGFR2-targeted cancer therapeutics. Hence, development of dual inhibitors on VEGFR2 and Src can be a useful strategy for such treatments. Materials & methods: A multistep virtual screening protocol, comprising ligand-based support vector machines method, drug-likeness rules filter and structure-based molecular docking, was developed and employed to identify dual inhibitors of VEGFR2 and Src from a large commercial chemical library. Kinase inhibitory assays and cell viability assays were then used for experimental validation. Results: A set of compounds belonging to six different molecular scaffolds was identified and sent for biological evaluation. Compound 3c belonging to the 2-amino-3-cyanopyridine scaffold exhibited good antiproliferative effect and dual-target activities against VEGFR2 and Src. Conclusion: This study demonstrated the ability of the multistep virtual screening approach to identify novel multitarget agents. © 2017 Future Science Ltd.
Design, synthesis and biological evaluation of 5-amino-1H-pyrazole-4-carboxamide derivatives as pan-FGFR covalent inhibitors

Wuqing Deng,Xiaojuan Chen,Hong Liang,Xiaojuan Song,Shuang Xiang,Jing Guo,Zhengchao Tu,Yang Zhou,Yongheng Chen,Xiaoyun Lu

DOI: https://doi.org/10.1016/j.ejmech.2024.116558

2024-09-05

Abstract:The aberrant activation of FGFRs plays a critical role in various cancers, leading to the development of several FGFR inhibitors in clinic. However, the emergence of drug resistance, primarily due to gatekeeper mutations in FGFRs, has limited their clinical efficacy. To address the unmet medical need, a series of 5-amino-1H-pyrazole-4-carboxamide derivatives were designed and synthesized as novel pan-FGFR covalent inhibitors targeting both wild-type and the gatekeeper mutants. The representative compound 10h demonstrated nanomolar activities against FGFR1, FGFR2, FGFR3 and FGFR2 V564F gatekeeper mutant in biochemical assays (IC50 = 46, 41, 99, and 62 nM). Moreover, 10h also strongly suppressed the proliferation of NCI-H520 lung cancer cells, SNU-16 and KATO III gastric cancer cells with IC50 values of 19, 59, and 73 nM, respectively. Further X-ray co-crystal structure revealed that 10h irreversibly binds to FGFR1. The study provides a new promising point for anticancer drug development medicated by FGFRs.
Fused in silico and bioactivity evaluation method for drug discovery: T001-10027877 was identified as an antiproliferative agent that targets EGFRT790M/C797S/L858R and EGFRT790M/L858R

Linxiao Wang,Xiaoling Huang,Shidi Xu,Yufeng An,Xinya Lv,Wufu Zhu,Shan Xu,Yuanbiao Tu,Shuhui Chen,Qiaoli Lv,Pengwu Zheng

DOI: https://doi.org/10.1186/s13065-024-01279-z

2024-08-27

Abstract:Background: Facing the significant challenge of overcoming drug resistance in cancer treatment, particularly resistance caused by mutations in epidermal growth factor receptor (EGFR), the aim of our study was to identify potent EGFR inhibitors effective against the T790M/C797S/L858R mutant, a key player in resistance mechanisms. Methods: Our integrated in silico approach harnessed machine learning, virtual screening, and activity evaluation techniques to screen 5105 compounds from three libraries, aiming to find candidates capable of overcoming the resistance conferred by the T790M and C797S mutations within EGFR. This methodical process narrowed the search down to six promising compounds for further examination. Results: Kinase assays identified three compounds to which the T790M/C797S/L858R mutant exhibited increased sensitivity compared to the T790M/L858R mutant, highlighting the potential efficacy of these compounds against resistance mechanisms. Among them, T001-10027877 exhibited dual inhibitory effects, with IC50 values of 4.34 µM against EGFRT790M/C797S/L858R and 1.27 µM against EGFRT790M/L858R. Further investigations into the antiproliferative effects in H1975, A549, H460 and Ba/F3-EGFRL858/T790M/C797S cancer cells revealed that T001-10027877 was the most potent anticancer agent among the tested compounds. Additionally, the induction of H1975 cell apoptosis and cell cycle arrest by T001-10027877 were confirmed, elucidating its mechanism of action. Conclusions: This study highlights the efficacy of combining computational techniques with bioactivity assessments in the quest for novel antiproliferative agents targeting complex EGFR mutations. In particular, T001-10027877 has great potential for overcoming EGFR-mediated resistance and merits further in vivo exploration. Our findings contribute valuable insights into the development of next-generation anticancer therapies, demonstrating the power of an integrated drug discovery approach.
Design, Synthesis, and Biological Evaluation of 3-Amino-pyrazine-2-carboxamide Derivatives As Novel FGFR Inhibitors

Jia Zheng,Wei Zhang,Dan Ni,Shuang Zhao,Yi He,Junchi Hu,Linfeng Li,Yongjun Dang,Zufeng Guo,Shenyou Nie

DOI: https://doi.org/10.1021/acsmedchemlett.4c00431

2024-01-01

ACS Medicinal Chemistry Letters

Abstract:FGFR has been considered a crucial oncogenic driver and promising target for cancer therapy. Herein, we reported the design and synthesis of 3-amino-N-(3,5-dihydroxyphenyl)-6-methylpyrazine-2-carboxamide derivatives as novel FGFR inhibitors. SAR exploration led to the identification of 18i as a pan-FGFR inhibitor with favorable in vitro activity against FGFR1-4. Moreover, 18i blocked the activation of FGFR and downstream signaling pathways at the submicromolar level and exhibited potent antitumor activity in multiple cancer cell lines with FGFR abnormalities. Molecular docking was performed to investigate the possible binding modes of 18i within the binding site of FGFR2. These results suggest that compound 18i is a promising candidate for further drug discovery.

Circulatory lability and myocardial stress in cardiovascular surgical patients.

Discovery of 4,6-Pyrimidinediamine Derivatives As Novel Dual EGFR/FGFR Inhibitors Aimed EGFR/FGFR1-positive NSCLC.

Design, synthesis, and biological evaluation of selective covalent inhibitors of FGFR4

Design, synthesis, and biological evaluation of 1,6-naphthyridine-2-one derivatives as novel FGFR4 inhibitors for the treatment of colorectal cancer

Discovery of potent CSK inhibitors through integrated virtual screening and molecular dynamic simulation

Virtual screening, molecular dynamics simulations, and in vitro validation of EGFR inhibitors as breast cancer therapeutics

Discovery of the First-in-Class Dual-Target ROCK/HDAC Inhibitor with Potent Antitumor Efficacy in Vivo That Trigger Antitumor Immunity

Discovery of Novel Epidermal Growth Factor Receptor (EGFR) Inhibitors Using Computational Approaches

High-Throughput Empirical and Virtual Screening to Discover Novel Inhibitors of Polyploid Giant Cancer Cells in Breast Cancer

Active and machine learning-enhanced discovery of new FGFR3 inhibitor, Rhapontin, through virtual screening of receptor structures and anti-cancer activity assessment

PO-462 Investigating the Potential Anti-Cancer Properties of a Novel Src Family Kinase Inhibitor in Triple Negative Breast Cancer

Discovery of Dual FGFR4 and EGFR Inhibitors by Machine Learning and Biological Evaluation

Design and synthesis of dual BRD4/Src inhibitors for treatment of triple-negative breast cancer

Identification of New EGFR Inhibitors by Structure-Based Virtual Screening and Biological Evaluation

Unveiling the therapeutic potential: KBU2046 halts triple-negative breast cancer cell migration by constricting TGF-β1 activation in vitro

Discovery of a small molecule ligand of FRS2 that inhibits invasion and tumor growth

Design, Synthesis, and Biological Evaluation of Aminoindazole Derivatives as Highly Selective Covalent Inhibitors of Wild-Type and Gatekeeper Mutant FGFR4

Discovery of novel dual VEGFR2 and Src inhibitors using a multistep virtual screening approach

Design, synthesis and biological evaluation of 5-amino-1H-pyrazole-4-carboxamide derivatives as pan-FGFR covalent inhibitors

Fused in silico and bioactivity evaluation method for drug discovery: T001-10027877 was identified as an antiproliferative agent that targets EGFRT790M/C797S/L858R and EGFRT790M/L858R

Design, Synthesis, and Biological Evaluation of 3-Amino-pyrazine-2-carboxamide Derivatives As Novel FGFR Inhibitors